Technical Analysis for BFRG - Bullfrog AI Holdings, Inc
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Up | Flat |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 20 DMA | Bearish | 0.00% | |
| 50 DMA Support | Bullish | 0.00% | |
| New Uptrend | Bullish | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Crossed Above 20 DMA | Bullish | -2.22% | |
| Crossed Above 50 DMA | Bullish | -2.22% | |
| 180 Bullish Setup | Bullish Swing Setup | -2.22% | |
| Wide Bands | Range Expansion | -2.22% | |
| 50 DMA Resistance | Bearish | 4.35% | |
| Wide Bands | Range Expansion | 4.35% |
| Alert | Time |
|---|---|
| 50 DMA Support | about 10 hours ago |
| 20 DMA Resistance | about 10 hours ago |
| 10 DMA Resistance | about 10 hours ago |
| Down 5% | about 10 hours ago |
| 2x Volume Pace | about 11 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: Unknown
Bullfrog AI Holdings, Inc Description
BullFrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. It offers bfLEAP, an AI/ML platform for the analysis of preclinical and/or clinical data. The company also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of human cancer or neoplastic disease. BullFrog AI Holdings, Inc. was founded in 2017 and is based in Gaithersburg, Maryland.
Classification
Sector: Healthcare
Industry: Health Information Services
Keywords: Medicine Artificial Intelligence Machine Learning Obesity Hepatitis Steatohepatitis Human Diseases Non Alcoholic Fatty Liver Disease Liver Disease Hepatocellular Carcinoma Histopathology Fatty Liver Disease Human Cancer Si RNA Treatment Of Human Diseases
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 8.35 |
| 52 Week Low | 1.4304 |
| Average Volume | 82,641 |
| 200-Day Moving Average | 3.14 |
| 50-Day Moving Average | 2.58 |
| 20-Day Moving Average | 2.68 |
| 10-Day Moving Average | 2.64 |
| Average True Range | 0.25 |
| RSI (14) | 50.25 |
| ADX | 25.3 |
| +DI | 22.83 |
| -DI | 11.30 |
| Chandelier Exit (Long, 3 ATRs) | 2.46 |
| Chandelier Exit (Short, 3 ATRs) | 2.89 |
| Upper Bollinger Bands | 3.16 |
| Lower Bollinger Band | 2.20 |
| Percent B (%b) | 0.46 |
| BandWidth | 35.86 |
| MACD Line | 0.02 |
| MACD Signal Line | 0.04 |
| MACD Histogram | -0.0203 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.00 | ||||
| Resistance 3 (R3) | 3.01 | 2.89 | 2.94 | ||
| Resistance 2 (R2) | 2.89 | 2.80 | 2.89 | 2.92 | |
| Resistance 1 (R1) | 2.77 | 2.75 | 2.71 | 2.76 | 2.90 |
| Pivot Point | 2.65 | 2.65 | 2.63 | 2.65 | 2.65 |
| Support 1 (S1) | 2.53 | 2.56 | 2.47 | 2.52 | 2.38 |
| Support 2 (S2) | 2.41 | 2.51 | 2.41 | 2.36 | |
| Support 3 (S3) | 2.29 | 2.41 | 2.34 | ||
| Support 4 (S4) | 2.28 |
